Condition
B-cell Tumors
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Not Yet Recruiting1
Recruiting1
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06461351RecruitingPrimary
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
NCT06567080Phase 1Not Yet RecruitingPrimary
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
NCT05932173Phase 1Unknown
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
NCT05560360Phase 1CompletedPrimary
A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
Showing all 4 trials